vs

Side-by-side financial comparison of Orion S.A. (OEC) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Orion S.A. is the larger business by last-quarter revenue ($411.7M vs $225.6M, roughly 1.8× Organogenesis Holdings Inc.). On growth, Organogenesis Holdings Inc. posted the faster year-over-year revenue change (78.1% vs -5.2%). Orion S.A. produced more free cash flow last quarter ($44.2M vs $34.8M). Over the past eight quarters, Organogenesis Holdings Inc.'s revenue compounded faster (43.2% CAGR vs -9.5%).

Orion Corporation, founded in 1917 and headquartered at Espoo, Finland, is a globally operating Finnish company which develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients for global markets. All of the company's manufacturing sites and the majority of its R&D units are in Finland.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

OEC vs ORGO — Head-to-Head

Bigger by revenue
OEC
OEC
1.8× larger
OEC
$411.7M
$225.6M
ORGO
Growing faster (revenue YoY)
ORGO
ORGO
+83.3% gap
ORGO
78.1%
-5.2%
OEC
More free cash flow
OEC
OEC
$9.4M more FCF
OEC
$44.2M
$34.8M
ORGO
Faster 2-yr revenue CAGR
ORGO
ORGO
Annualised
ORGO
43.2%
-9.5%
OEC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
OEC
OEC
ORGO
ORGO
Revenue
$411.7M
$225.6M
Net Profit
$43.7M
Gross Margin
18.9%
Operating Margin
4.3%
28.1%
Net Margin
19.4%
Revenue YoY
-5.2%
78.1%
Net Profit YoY
469.5%
EPS (diluted)
$-0.36
$0.31

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OEC
OEC
ORGO
ORGO
Q4 25
$411.7M
$225.6M
Q3 25
$450.9M
$150.9M
Q2 25
$466.4M
$101.0M
Q1 25
$477.7M
$86.7M
Q4 24
$434.2M
$126.7M
Q3 24
$463.4M
$115.2M
Q2 24
$477.0M
$130.2M
Q1 24
$502.9M
$110.0M
Net Profit
OEC
OEC
ORGO
ORGO
Q4 25
$43.7M
Q3 25
$-67.1M
$21.6M
Q2 25
$9.0M
$-9.4M
Q1 25
$9.1M
$-18.8M
Q4 24
$7.7M
Q3 24
$-20.2M
$12.3M
Q2 24
$20.5M
$-17.0M
Q1 24
$26.7M
$-2.1M
Gross Margin
OEC
OEC
ORGO
ORGO
Q4 25
18.9%
Q3 25
19.0%
Q2 25
21.1%
Q1 25
20.5%
72.6%
Q4 24
20.6%
75.5%
Q3 24
23.2%
76.7%
Q2 24
23.0%
77.6%
Q1 24
24.3%
73.9%
Operating Margin
OEC
OEC
ORGO
ORGO
Q4 25
4.3%
28.1%
Q3 25
-11.9%
13.7%
Q2 25
6.9%
-12.5%
Q1 25
6.5%
-30.9%
Q4 24
5.4%
8.1%
Q3 24
-3.3%
5.4%
Q2 24
8.7%
-10.7%
Q1 24
10.5%
-3.5%
Net Margin
OEC
OEC
ORGO
ORGO
Q4 25
19.4%
Q3 25
-14.9%
14.3%
Q2 25
1.9%
-9.3%
Q1 25
1.9%
-21.7%
Q4 24
6.1%
Q3 24
-4.4%
10.7%
Q2 24
4.3%
-13.1%
Q1 24
5.3%
-1.9%
EPS (diluted)
OEC
OEC
ORGO
ORGO
Q4 25
$-0.36
$0.31
Q3 25
$-1.20
$0.11
Q2 25
$0.16
$-0.10
Q1 25
$0.16
$-0.17
Q4 24
$0.31
$0.05
Q3 24
$-0.35
$0.09
Q2 24
$0.35
$-0.13
Q1 24
$0.45
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OEC
OEC
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$60.7M
$93.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$384.6M
$300.1M
Total Assets
$1.9B
$598.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OEC
OEC
ORGO
ORGO
Q4 25
$60.7M
$93.7M
Q3 25
$51.3M
$63.7M
Q2 25
$42.6M
$73.1M
Q1 25
$37.5M
$110.0M
Q4 24
$44.2M
$135.6M
Q3 24
$53.2M
$94.3M
Q2 24
$34.2M
$89.9M
Q1 24
$43.9M
$88.6M
Total Debt
OEC
OEC
ORGO
ORGO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Q1 24
$65.2M
Stockholders' Equity
OEC
OEC
ORGO
ORGO
Q4 25
$384.6M
$300.1M
Q3 25
$401.8M
$255.1M
Q2 25
$466.5M
$233.2M
Q1 25
$466.1M
$242.9M
Q4 24
$474.9M
$262.9M
Q3 24
$476.3M
$278.5M
Q2 24
$503.9M
$263.5M
Q1 24
$492.2M
$278.0M
Total Assets
OEC
OEC
ORGO
ORGO
Q4 25
$1.9B
$598.7M
Q3 25
$2.0B
$509.8M
Q2 25
$2.0B
$461.1M
Q1 25
$2.0B
$467.4M
Q4 24
$1.9B
$497.9M
Q3 24
$2.0B
$446.3M
Q2 24
$1.9B
$443.2M
Q1 24
$1.9B
$458.5M
Debt / Equity
OEC
OEC
ORGO
ORGO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×
Q1 24
0.23×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OEC
OEC
ORGO
ORGO
Operating Cash FlowLast quarter
$92.9M
$39.4M
Free Cash FlowOCF − Capex
$44.2M
$34.8M
FCF MarginFCF / Revenue
10.7%
15.4%
Capex IntensityCapex / Revenue
11.8%
2.1%
Cash ConversionOCF / Net Profit
0.90×
TTM Free Cash FlowTrailing 4 quarters
$54.8M
$-24.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OEC
OEC
ORGO
ORGO
Q4 25
$92.9M
$39.4M
Q3 25
$68.8M
$3.1M
Q2 25
$53.7M
$-32.9M
Q1 25
$400.0K
$-19.9M
Q4 24
$94.5M
$10.9M
Q3 24
$-30.9M
$8.7M
Q2 24
$29.3M
$4.7M
Q1 24
$32.4M
$-10.2M
Free Cash Flow
OEC
OEC
ORGO
ORGO
Q4 25
$44.2M
$34.8M
Q3 25
$27.9M
$844.0K
Q2 25
$11.5M
$-36.5M
Q1 25
$-28.8M
$-23.6M
Q4 24
$23.5M
$7.6M
Q3 24
$-78.8M
$6.1M
Q2 24
$-25.4M
$2.9M
Q1 24
$-700.0K
$-12.4M
FCF Margin
OEC
OEC
ORGO
ORGO
Q4 25
10.7%
15.4%
Q3 25
6.2%
0.6%
Q2 25
2.5%
-36.1%
Q1 25
-6.0%
-27.2%
Q4 24
5.4%
6.0%
Q3 24
-17.0%
5.3%
Q2 24
-5.3%
2.2%
Q1 24
-0.1%
-11.3%
Capex Intensity
OEC
OEC
ORGO
ORGO
Q4 25
11.8%
2.1%
Q3 25
9.1%
1.5%
Q2 25
9.0%
3.6%
Q1 25
6.1%
4.2%
Q4 24
16.4%
2.7%
Q3 24
10.3%
2.2%
Q2 24
11.5%
1.4%
Q1 24
6.6%
2.0%
Cash Conversion
OEC
OEC
ORGO
ORGO
Q4 25
0.90×
Q3 25
0.14×
Q2 25
5.97×
Q1 25
0.04×
Q4 24
1.43×
Q3 24
0.71×
Q2 24
1.43×
Q1 24
1.21×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

OEC
OEC

Rubber$272.0M66%
Specialties$139.7M34%

ORGO
ORGO

Segment breakdown not available.

Related Comparisons